Avidity Biosciences (RNA) Competitors $31.82 +0.77 (+2.48%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends RNA vs. MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, PCVX, QGEN, and ITCIShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Moderna (NASDAQ:MRNA) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do analysts prefer MRNA or RNA? Moderna presently has a consensus target price of $79.50, indicating a potential upside of 101.83%. Avidity Biosciences has a consensus target price of $64.36, indicating a potential upside of 102.27%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.14Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, MRNA or RNA? Moderna has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Does the media refer more to MRNA or RNA? In the previous week, Moderna had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 21 mentions for Moderna and 20 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.52 beat Moderna's score of 0.20 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, MRNA or RNA? Avidity Biosciences has lower revenue, but higher earnings than Moderna. Avidity Biosciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$5.06B3.00-$4.71B-$5.82-6.77Avidity Biosciences$10.12M375.25-$212.22M-$2.88-11.05 Do insiders & institutionals have more ownership in MRNA or RNA? 75.3% of Moderna shares are owned by institutional investors. 15.7% of Moderna shares are owned by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is MRNA or RNA more profitable? Moderna has a net margin of -43.77% compared to Avidity Biosciences' net margin of -2,772.45%. Moderna's return on equity of -17.68% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Moderna-43.77% -17.68% -13.35% Avidity Biosciences -2,772.45%-27.66%-24.56% Does the MarketBeat Community believe in MRNA or RNA? Moderna received 56 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 67.53% of users gave Avidity Biosciences an outperform vote while only 55.21% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21255.21% Underperform Votes17244.79% Avidity BiosciencesOutperform Votes15667.53% Underperform Votes7532.47% SummaryModerna beats Avidity Biosciences on 11 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.80B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-11.0510.5991.3417.19Price / Sales375.25195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book4.715.104.794.78Net Income-$212.22M$151.51M$120.07M$225.60M7 Day Performance-2.06%-2.15%-1.90%-1.23%1 Month Performance-25.50%-3.14%11.45%3.37%1 Year Performance250.44%11.50%30.63%16.58% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.1843 of 5 stars$31.82+2.5%$64.36+102.3%+278.8%$3.80B$10.12M-11.05190Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeMRNAModerna4.2664 of 5 stars$41.59-0.6%$79.50+91.2%-54.3%$16.00B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0581 of 5 stars$12.71+0.6%$13.67+7.5%+19.8%$15.17B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2766 of 5 stars$18.71+4.9%$33.33+78.2%+636.9%$13.80B$700,000.00-63.68105News CoverageGMABGenmab A/S4.2355 of 5 stars$20.14-0.1%$45.20+124.4%-33.5%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8548 of 5 stars$14.75+2.0%$17.00+15.3%+15.8%$12.31B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$126.12+1.9%$178.71+41.7%+31.8%$12.05B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6049 of 5 stars$90.59+3.3%$147.50+62.8%+45.4%$11.29BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.7415 of 5 stars$45.41+0.0%$51.15+12.6%+3.1%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0406 of 5 stars$84.54+1.8%$97.23+15.0%+27.8%$8.96B$612.78M-95.91560 Related Companies and Tools Related Companies Moderna Competitors Viatris Competitors Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Catalent Competitors Vaxcyte Competitors Qiagen Competitors Intra-Cellular Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts